IN2012DN03187A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03187A IN2012DN03187A IN3187DEN2012A IN2012DN03187A IN 2012DN03187 A IN2012DN03187 A IN 2012DN03187A IN 3187DEN2012 A IN3187DEN2012 A IN 3187DEN2012A IN 2012DN03187 A IN2012DN03187 A IN 2012DN03187A
- Authority
- IN
- India
- Prior art keywords
- present
- glp
- treat
- muscle atrophy
- prevent muscle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 3
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
- 206010028289 Muscle atrophy Diseases 0.000 abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
- 230000020763 muscle atrophy Effects 0.000 abstract 2
- 201000000585 muscular atrophy Diseases 0.000 abstract 2
- 230000035764 nutrition Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09172398A EP2311486A1 (en) | 2009-10-07 | 2009-10-07 | GLP-2 for use in intestine and muscle recovery |
PCT/EP2010/065021 WO2011042501A2 (en) | 2009-10-07 | 2010-10-07 | The intestine and muscle recovery |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03187A true IN2012DN03187A (tr) | 2015-09-25 |
Family
ID=41611235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3187DEN2012 IN2012DN03187A (tr) | 2009-10-07 | 2010-10-07 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120270786A1 (tr) |
EP (2) | EP2311486A1 (tr) |
JP (1) | JP5801814B2 (tr) |
CN (1) | CN102711803B (tr) |
AU (1) | AU2010305420B2 (tr) |
BR (1) | BR112012009380A2 (tr) |
CA (1) | CA2776964C (tr) |
DK (1) | DK2485756T3 (tr) |
ES (1) | ES2539917T3 (tr) |
HK (1) | HK1173949A1 (tr) |
IN (1) | IN2012DN03187A (tr) |
WO (1) | WO2011042501A2 (tr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015025490B1 (pt) * | 2013-04-15 | 2022-05-03 | Société des Produits Nestlé S.A. | Uso de uma fonte de aminoácidos em combinação com o estímulo muscular elétrico |
JP6325215B2 (ja) * | 2013-08-29 | 2018-05-16 | テルモ株式会社 | 栄養補給用冷菓 |
CA2963182C (en) * | 2014-10-14 | 2023-10-17 | Nestec S.A. | Improvement in muscle functionality of elderly males |
US10993993B2 (en) | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
KR101661332B1 (ko) * | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 |
KR102119188B1 (ko) * | 2018-11-13 | 2020-06-08 | 이뮤노포지 주식회사 | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5661123A (en) * | 1995-01-17 | 1997-08-26 | Nestec, Ltd. | Enteral composition for malabsorbing patients |
US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US6852690B1 (en) * | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
EP0906338B1 (en) * | 1996-04-12 | 2002-11-06 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
EP1090636A1 (en) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
EP1970072A1 (en) * | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US7112567B2 (en) * | 2001-02-16 | 2006-09-26 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
BR0314920A (pt) * | 2002-10-14 | 2005-08-02 | Novo Nordisk As | Peptìdeo glp-2, construto de polinucleotìdeo, célula hospedeira, derivado de glp-2 compreendendo um peptìdeo glp-2, composição farmacêutica, uso de um derivado de glp-2, método para o tratamento de uma insuficiência intestinal ou outra condição acarretando a má absorção de nutrientes no intestino, método para o tratamento de doenças, e, método para produzir o peptìdeo glp-2 |
US20040115708A1 (en) * | 2002-10-28 | 2004-06-17 | Ardies C. Murray | Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia |
CN1822851B (zh) * | 2003-05-15 | 2011-04-13 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
EP1868454B1 (en) * | 2005-04-06 | 2013-03-06 | Nestec S.A. | Composition for nutritionally improving glucose control and insulin action |
CA2631220A1 (en) * | 2006-01-09 | 2007-07-19 | Nestec S.A. | Treatment of stressed patients |
CA2669806C (en) * | 2006-11-08 | 2018-10-02 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
-
2009
- 2009-10-07 EP EP09172398A patent/EP2311486A1/en not_active Withdrawn
-
2010
- 2010-10-07 US US13/500,784 patent/US20120270786A1/en not_active Abandoned
- 2010-10-07 DK DK10762684.8T patent/DK2485756T3/en active
- 2010-10-07 WO PCT/EP2010/065021 patent/WO2011042501A2/en active Application Filing
- 2010-10-07 CA CA2776964A patent/CA2776964C/en active Active
- 2010-10-07 IN IN3187DEN2012 patent/IN2012DN03187A/en unknown
- 2010-10-07 EP EP10762684.8A patent/EP2485756B1/en active Active
- 2010-10-07 JP JP2012532595A patent/JP5801814B2/ja active Active
- 2010-10-07 ES ES10762684.8T patent/ES2539917T3/es active Active
- 2010-10-07 CN CN201080055259.6A patent/CN102711803B/zh active Active
- 2010-10-07 BR BR112012009380-0A patent/BR112012009380A2/pt not_active Application Discontinuation
- 2010-10-07 AU AU2010305420A patent/AU2010305420B2/en active Active
-
2013
- 2013-01-22 HK HK13100959.4A patent/HK1173949A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1173949A1 (en) | 2013-05-31 |
BR112012009380A2 (pt) | 2021-06-22 |
JP2013507341A (ja) | 2013-03-04 |
CA2776964C (en) | 2019-03-05 |
EP2485756B1 (en) | 2015-05-20 |
WO2011042501A2 (en) | 2011-04-14 |
US20120270786A1 (en) | 2012-10-25 |
AU2010305420B2 (en) | 2015-03-19 |
ES2539917T3 (es) | 2015-07-07 |
WO2011042501A3 (en) | 2011-06-03 |
DK2485756T3 (en) | 2015-06-08 |
EP2485756A2 (en) | 2012-08-15 |
EP2311486A1 (en) | 2011-04-20 |
JP5801814B2 (ja) | 2015-10-28 |
AU2010305420A1 (en) | 2012-05-10 |
CA2776964A1 (en) | 2011-04-14 |
CN102711803A (zh) | 2012-10-03 |
CN102711803B (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268519A (en) | Useful preparations in the treatment of spinal muscular atrophy | |
IN2012DN01638A (tr) | ||
MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
IL210810A0 (en) | Compositions for the treatment of pain and/or inflamtion | |
JO2975B1 (en) | Formulation to improve sexual health | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MY153948A (en) | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | |
EP2384198A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES | |
MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
IL184312A0 (en) | Herbal compositions for the treatment of diabetes and/or conditions associated therewith | |
MY159856A (en) | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders | |
IN2012DN00624A (tr) | ||
IN2012DN02624A (tr) | ||
IN2012DN03187A (tr) | ||
HK1173379A1 (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
ZA201109086B (en) | Prevention and treatment of allergic diarrhoea | |
MX369699B (es) | Ácido graso del aceite de bogol para uso en suplementos y composiciones de tratamiento y piensos para animales. | |
WO2011044523A3 (en) | Compositions and methods for treating obesity | |
MX2011011860A (es) | Composicion estimulante inmune que comprende un extracto de aronia sp. en combinacion con selenio y/o zinc. | |
MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
EP2597949A4 (en) | SUBMIKROMETERZUSAMMENSETZUNGEN | |
PL2375912T3 (pl) | Kompozycje i sposoby leczenia uczucia dyskomfortu gardła | |
MX2018007398A (es) | Composicion para mejorar la sensacion bucal. | |
GB201312583D0 (en) | Combination and composition for treating obesity |